Skip to main content
50°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
89.51
+0.69 (+0.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
October 30, 2024
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Via
Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
These stocks are trading at less than 15 times their expected future profits.
Via
The Motley Fool
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
October 22, 2024
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.
Via
Talk Markets
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
October 21, 2024
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success...
Via
Benzinga
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
October 21, 2024
Via
Benzinga
Peering Into Gilead Sciences's Recent Short Interest
October 21, 2024
Via
Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
October 21, 2024
Via
Benzinga
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
October 17, 2024
Via
Benzinga
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
October 21, 2024
Via
Benzinga
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
October 18, 2024
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...
Via
Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 17, 2024
Via
Benzinga
Will GILEAD SCIENCES INC breakout?
October 14, 2024
Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC.
Via
Chartmill
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
October 04, 2024
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
October 01, 2024
Via
Benzinga
News Is Noise
September 23, 2024
Via
Talk Markets
Biotech Stocks Poised For Another Big Move In Q4
October 07, 2024
The healthcare sector can be a safe haven if volatility increases.
Via
Talk Markets
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night
September 24, 2024
Via
Benzinga
Gilead Sciences Unusual Options Activity For September 20
September 20, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
September 13, 2024
Via
Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
September 23, 2024
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining...
Via
Benzinga
Topics
Product Recall
Exposures
COVID-19
Legal
Product Safety
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
September 23, 2024
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment.
Via
Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
Bargain hunters should love these great stocks.
Via
The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 20, 2024
Via
Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
These two stocks have had their issues in recent years, but both look like reliable long-term bets.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Why Gilead Sciences Stock Thrashed the Market Today
September 12, 2024
In drug development, solid performance in large-scale clinical trials is crucial.
Via
The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
September 12, 2024
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, outperforming once-daily Truvada. Global regulatory filings are expected by...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.